NCT05489237View on ClinicalTrials.gov

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

269

Participants

Timeline

Start Date

August 3, 2022

Primary Completion Date

March 10, 2027

Study Completion Date

November 3, 2027

Conditions
Gastrointestinal NeoplasmsGastrointestinal Stromal Tumor (GIST)Digestive System DiseaseGastrointestinal DiseasesMetastatic Cancer
Interventions
DRUG

IDRX-42

Administered at assigned doses and schedules once or twice daily in continuous cycles of 28 days each.

Trial Locations (18)

5505

RECRUITING

GSK Investigational Site, Seoul

10065

RECRUITING

GSK Investigational Site, New York

13005

RECRUITING

GSK Investigational Site, Marseille

20133

RECRUITING

GSK Investigational Site, Milan

33076

RECRUITING

GSK Investigational Site, Bordeaux

33146

RECRUITING

GSK Investigational Site, Miami

63129

RECRUITING

GSK Investigational Site, St Louis

94805

RECRUITING

GSK Investigational Site, Villejuif

97239

RECRUITING

GSK Investigational Site, Portland

100142

RECRUITING

GSK Investigational Site, Beijing

02215

RECRUITING

GSK Investigational Site, Boston

Unknown

RECRUITING

GSK Investigational Site, Lyon

RECRUITING

GSK Investigational Site, Barcelona

277-8577

RECRUITING

GSK Investigational Site, Chiba

104-0045

RECRUITING

GSK Investigational Site, Tokyo

1066 CX

RECRUITING

GSK Investigational Site, Amsterdam

LS9 7TF

RECRUITING

GSK Investigational Site, Leeds

SW3 6JJ

RECRUITING

GSK Investigational Site, London

All Listed Sponsors
lead

IDRx Inc. - A GSK Company

INDUSTRY